You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Respiratory products

Please find a list of our respiratory products below.

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol)

Prescribing information

Trelegy Ellipta is indicated for the maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. [1]

Anoro Ellipta (umeclidinium / vilanterol inhalation powder)

Prescribing information

Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).[2]

Incruse Ellipta (umeclidinium)

Prescribing information

Incruse is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. [3]

Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)

Prescribing information

Asthma

Relvar Ellipta (92 micrograms/22 micrograms inhalation powder and 184 micrograms/22 micrograms inhalation powder) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists. [4][5]

Chronic Obstructive Pulmonary Disease (COPD)

Relvar Ellipta (92 micrograms/22 micrograms inhalation powder) is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy. [4]

Incruse Ellipta and Relvar Ellipta (umeclidinium and fluticasone furoate / vilanterol inhalation powder)

Incruse in combination with Relvar for your COPD patients suitable for a LAMA + ICS/LABA.

Nucala (mepolizumab)

Prescribing information

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. [6]

Seretide 50/100, 50/250, 50/500 Accuhaler

Asthma

Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist

or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Note: Seretide 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma. [7]

Chronic Obstructive Pulmonary Disease (COPD)

Seretide is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. [7]

Seretide 25/50, 25/125, 25/250 Evohaler

Asthma

Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short- acting β2 agonist

or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist. [8]

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Trade marks are owned by or licensed to the GSK group of companies 

N.M. Last updated: November 2017. UK/RESP/0485/15b(3)